지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 630 - 637 (8page)
이용수
초록· 키워드
오류제보하기
Purpose Platinum-based doublet chemotherapy is the treatment of choice for patients withnon-small cell lung cancer (NSCLC); however, the role of a platinum-based doublet assecond-line therapy after failure of an epidermal growth factor receptor (EGFR) tyrosinekinase inhibitor (TKI) for NSCLC patients has not yet been elucidated. The purpose of thisstudy was to compare the clinical efficacy of pemetrexed versus a platinum-based doubletas second-line therapy after failure of EGFR TKI used as first-line therapy for NSCLC patientswith EGFR mutations.
Materials and MethodsWe designed a multicenter retrospective cohort study of 314 NSCLC patients with EGFRmutations who received an EGFR TKI as first-line palliative chemotherapy. Our analysisincluded 83 patients who failed EGFR TKI therapy and received second-line cytotoxicchemotherapy.
ResultsForty-six patients were treated using a platinum-based doublet and 37 patients were treatedusing singlet pemetrexed. The overall response rates of patients receiving a platinum-baseddoublet and patients receiving pemetrexed were17.4% and 32.4%, respectively (p=0.111).
The median progression-free survival (PFS) of patients receiving pemetrexed was significantlylonger than that of patients receiving a platinum-based doublet (4.2 months vs. 2.7months, respectively; p=0.008). The hazard ratio was 0.54 (95% confidence interval, 0.34to 0.86; p=0.009).
ConclusionOur retrospective analysis found that second-line pemetrexed singlet therapy providedsignificantly prolonged PFS compared to second-line platinum-based doublet chemotherapyfor NSCLC patients with EGFRmutations who failed first-line EGFR TKI. Conduct of prospectivestudies for confirmation of our results is warranted.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Azzoli CG / 2009 / American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-smallcell lung cancer / J Clin Oncol 27 : 6251 ~
Eisenhauer EA / 2009 / New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) / Eur J Cancer 45 : 228 ~ 247
Gridelli C / 2003 / Chemotherapy for elderly patients with advanced non-small-cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study(MILES)phase III ran
Han JY / 2012 / First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung / J Clin Oncol 30 : 1122
Hirsch FR / 2009 / EGFR testing in lung cancer is ready for prime time / Lancet Oncol 10 : 432 ~ 433
Eisenhauer EA / 2009 / New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) / Eur J Cancer 45 : 228 ~ 247
Gridelli C / 2003 / Chemotherapy for elderly patients with advanced non-small-cell lung cancer : the Multicenter Italian Lung Cancer in the Elderly Study(MILES)phase III ran
Han JY / 2012 / First-SIGNAL : first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung / J Clin Oncol 30 : 1122
Hirsch FR / 2009 / EGFR testing in lung cancer is ready for prime time / Lancet Oncol 10 : 432 ~ 433
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
Tuberculosis and Respiratory Diseases
2018 .01
-
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Cancer Research and Treatment
2019 .01
-
Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Tuberculosis and Respiratory Diseases
2017 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
Pemetrexed in Treating Patients with Metastatic Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Cancer Research and Treatment
2023 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Yonsei Medical Journal
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0